EVA1A and hepatocellular carcinoma: Western blot assessment of the expression of EVA1A in HCC cells treated with pCDH-miR-125b or anti-miR-125b or their respective controls showed that EVA1A expression was higher in oxaliplatin-resistant than in oxaliplatin-sensitive cells, and miR-125b downregulated EVA1A in oxaliplatin-resistant cells, whereas inhibition of miR-125b upregulated EVA1A in oxaliplatin-sensitive cells (Figs. 4c, d).